3 US approvals within 12 months (Mcap 35 Mio$)

Replies to This Discussion

Permalink Reply by Chas on March 19, 2010 at 1:36pm

Time to buy?

• ▶ Reply

Permalink Reply by Carl Pechstein on March 22, 2010 at 12:09pm

GET IN BEFORE ITS TOO LATE ....

US APPROVAL IS COMING VERY SOON .IPCI WILL GO OVER 10$ EASILY !!

IntelliPharmaceutics (IPCI)

Market Cap: 35 Mio$
Cash: 8 Mio$
Price: 3,23 $

Shares Out: 10,9 M (CEO HOLDS 6 M SHARES )


UPCOMING MILESTONES 2010 ::

FOCALIN XR (ADHD) (Sales 350M$) MARKET APPROVAL IN 1H 2010

EFFEXOR XR (DEPRESSION) (Sales 3,9 B$) PIII RESULTS + US PARTNERSHIP in 2Q/3Q 2010


FILE AND HAVE ACCEPTED FOR REVIEW BY THE FDA
, TWO ADDITIONAL ANDA APPLICATION IN 2010





Intellipharmaceutics International Inc. (IPCI) engages in the research, development and commercialization of controlled-release drug technologies. The Company has 15 drug programs in development that address various therapeutic areas, including neurology, cardiovascular, Gastro-Intestinal Tract (GIT), pain and infection. Partnered with Par Pharmaceutical Companies Inc., the Company's lead drug product, a generic form of Focalin XR, is under review by the Food and Drug Administration for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Another one of the Company's leading drug candidate is Rexista, a competing drug to Oxycodone, developed to alleviate pain.


"With the development of its four leading drug products, including Generic Focalin XR, Generic Effexor XR, Rexista (Oxycodone) and Generic Coreg CR, the Company attempts to capture a portion of a combined market of more than $6.0 billion in annual revenue. Presently, revenue derived from its competitors' proprietary drugs Focalin XR, Effexor XR, Coreg CR and Oxycodone RX total $350 million, $3.9 billion, $300 million and $2.0 billion, respectively.

"The novel approach of manipulating the delivery of the above-named drug therapies via the Company's novel Hypermatrix(TM) concept allows the Company a margin of competitive advantage within the pharmaceutical space. Its Hypermatrix delivery system concept is designed to optimize Nature's hyper-dimensionality as it relates to drug therapies."

• ▶ Reply

Permalink Reply by Carl Pechstein on May 6, 2010 at 11:28am

Good news out today ...

15 Drugs in Pipeline ..Market Cap at 27 Million$ is wayyyyy Undervalued .

First Approval could happen any day now ..


http://files.shareholder.com/downloads/ABEA-43EQSZ/907395127x0x3606...

TWST: What does your investor base look like?

Dr. Odidi: Insiders and management own approximately 55% of the shares outstanding, providing for a very motivated management team. Par pharmaceutical owns just over 3.5%. The rest of the shares are widely held.

TWST: What makes IntelliPharmaCeutics a good company to have in one’s portfolio?

Dr. Odidi: I believe that this is both a current value play and a growth story. With 15 products in our pipeline and one currently awaiting FDA approval, I do not believe that our present market capitalization is reflective of our current situation. Furthermore, we have a number of key milestones for 2010 that I believe can further enhance shareholder value. These include: File and have accepted by the FDA additional ANDA’s; establish additional development and marketing alliances; complete manufacturing scale-up of clinical batches of Rexista for use in clinical trials; complete Phase I studies using clinical batches of Rexista; meet with FDA to discuss Rexista clinical development plan.



TWST: Obviously, many companies have been hurt by the current economic situation. Have you had to make adjustments to deal with the economic problems?

Dr. Odidi: We have always managed our company to be flexible to accommodate changing economic conditions. While the economic situation did cause us to reduce the number of active pipeline products in development, the cash received from our recent transaction has allowed us to re-accelerate the development of our pipeline. As such, in addition to our Focalin product, we would expect to have additional products filed for approval with the FDA prior to the end of 2010.

• ▶ Reply

Permalink Reply by Carl Pechstein on May 7, 2010 at 12:09pm

More good news ........

FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Effexor XR(R)
http://finance.yahoo.com/news/FDA-Accepts-for-Filing-pz-3713650139....

• ▶ Reply

Permalink Reply by Carl Pechstein on May 19, 2010 at 10:52am

Another great buying opportunity !!!!!!!!!!!!!!!! GLTA

Upcoming Milestones

distribution partner for effexor in 2Q / 3Q 2010

approval for focalin in 2Q 2010

• ▶ Reply

Permalink Reply by Joseph D on June 10, 2010 at 12:46pm

What's the latest news on IPCI? I haven't see a whole lot of activity.

• ▶ Reply

Permalink Reply by Carl Pechstein on June 14, 2010 at 6:13am

Great News today ...Market cap of 24 Million$ is wayyyy undervalued !!!

Intellipharmaceutics Files ANDA With the FDA for Generic Protonix(R)
http://finance.yahoo.com/news/Intellipharmaceutics-Files-pz-3029377...

"I am extremely pleased with the progress we continue to make with the advancement of our product pipeline," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "Protonix is the second ANDA we have filed with the FDA this year and, together with Focalin XR and Effexor XR, it represents another potential source of future revenue from our Company's ANDA pipeline."

• ▶ Reply

Permalink Reply by Carl Pechstein on June 14, 2010 at 12:12pm

RALLLYYYYYTIMEEEEEE........

US Approval + Partner Deal is coming soon .......

2010 Milestones :

Potential FDA approval of FocalinXR

File and have accepted for review by the FDA, two additional ANDA applications

Establish at least one additional development/marketing alliance

Complete manufacturing of clinical batches of Rexista™

Complete Phase 1 studies using clinical batches of Rexista™

Schedule a pre-IND meeting with FDA to discuss Rexista™ clinical development plan

• ▶ Reply

Permalink Reply by Carl Pechstein on June 15, 2010 at 2:48am

UPDATE...

IPCI is still significantly Undervalued . Please do your own Research .

FDA approval and Marketing Partner are next big Milestone in 2010 .


Very Bullish Chart ( Strong Buy - Rating)
http://www.barchart.com/quotes/stocks/IPCI


IntelliPharmaceutics (IPCI)

Market Cap: 30 Mio$
Price: 2,94 $

Shares Out: 10,9 M ... (CEO owns 6 Million Shares)


BioFianance Presentation April 2010
http://www.intellipharmaceutics.com/common/download/download.cfm?co...


Big Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm

More about IPCI
http://www.blackbusinessprofile.com/business-news/black-business-ar...


2010 Milestones :

Potential FDA approval of FocalinXR

File and have accepted for review by the FDA, two additional ANDA applications

Establish at least one additional development/marketing alliance

Complete manufacturing of clinical batches of Rexista™

Complete Phase 1 studies using clinical batches of Rexista™

Schedule a pre-IND meeting with FDA to discuss Rexista™ clinical development plan


Intellipharmaceutics International Inc. (IPCI) engages in the research, development and commercialization of controlled-release drug technologies. The Company has 15 drug programs in development that address various therapeutic areas, including neurology, cardiovascular, Gastro-Intestinal Tract (GIT), pain and infection. Partnered with Par Pharmaceutical Companies Inc., the Company's lead drug product, a generic form of Focalin XR, is under review by the Food and Drug Administration for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Another one of the Company's leading drug candidate is Rexista, a competing drug to Oxycodone, developed to alleviate pain.


"With the development of its four leading drug products, including Generic Focalin XR, Generic Effexor XR, Rexista (Oxycodone) and Generic Coreg CR, the Company attempts to capture a portion of a combined market of more than $6.0 billion in annual revenue. Presently, revenue derived from its competitors' proprietary drugs Focalin XR, Effexor XR, Coreg CR and Oxycodone RX total $350 million, $3.9 billion, $300 million and $2.0 billion, respectively.

"The novel approach of manipulating the delivery of the above-named drug therapies via the Company's novel Hypermatrix(TM) concept allows the Company a margin of competitive advantage within the pharmaceutical space. Its Hypermatrix delivery system concept is designed to optimize Nature's hyper-dimensionality as it relates to drug therapies."

• ▶ Reply

Permalink Reply by Carl Pechstein on June 15, 2010 at 9:54am

will go over 3$ today ..still a great buying opportunity !

• ▶ Reply

• ‹ Previous
• 1
• 2
• Next ›
• Page